Scholars@Duke
Glenn Jay Jaffe

Glenn Jay Jaffe

Robert Machemer M.D. Distinguished Professor of Ophthalmology
Ophthalmology, Vitreoretinal Diseases & Surgery
Box 3802 Med Ctr, Durham, NC 27710
Duke Eye Center, 2351 Erwin Ro, Durham, NC 27710

Overview

I have an active basic and clinical research program. I have been principal investigator on several funded clinical studies including investigations of an oral ganciclovir prodrug to treat CMV retinitis and a study to determine the safety of a cyclosporine sustained drug delivery implant in the treatment of uveitis. I am principal investigator of an ongoing multicenter trial of a fluocinolone sustained drug delivery implant to treat patients with severe uveitis and a trial of this same implant to treat diabetic macular edema. Recently, I have investigated the use of ultrasonography and optical coherence tomography to diagnose macular edema in a variety of ocular diseases. I have maintained an ongoing basic research program to test the hypothesis that cytokines are important in the development of proliferative vitreoretinopathy, an important intraocular wound healing disorder. Education: I am actively involved in resident and fellow education. I give lectures to residents and fellows on a variety of topics related to uveitis and vitreoretinal diseases and train fellows to perform vitreoretinal surgery. I train post-doctoral students and medical students to conduct clinically relevant research. I serve as a mentor for the Duke third year medical school research program. I have served on a yearly basis as course faculty at many national and international meetings.

Current Appointments & Affiliations

Robert Machemer M.D. Distinguished Professor of Ophthalmology · 2013 - Present Ophthalmology, Vitreoretinal Diseases & Surgery, Ophthalmology
Professor of Ophthalmology · 1998 - Present Ophthalmology, Vitreoretinal Diseases & Surgery, Ophthalmology
Chief, Division of Retinal Ophthalmology · 2008 - Present Ophthalmology, Vitreoretinal Diseases & Surgery, Ophthalmology

In the News

Published September 8, 2016
Humira Provides Effective, Non-Steroid Alternative for Eye Inflammation

View All News

Recent Publications

Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial.

Journal Article Ophthalmology · April 2026 PURPOSE: Avacincaptad pegol (ACP) is a pegylated RNA aptamer that inhibits complement C5. The efficacy and safety of ACP 2 mg was investigated in GATHER2, with positive year 1 results published. Herein, 2-year results are reported. DESIGN: Phase 3, randomi ... Full text Link to item Cite

Geographic Atrophy on Fundus Autofluorescence and Color Fundus Photographs: Association with Deep Visual Sensitivity Losses.

Journal Article Ophthalmol Sci · April 2026 PURPOSE: To determine the functional characteristics of color fundus photograph (CFP)- and fundus autofluorescence (FAF)-defined geographic atrophy (GA) lesions by evaluating the prevalence of repeatable deep visual sensitivity defects. DESIGN: Reader stud ... Full text Link to item Cite

Long-term Efficacy and Safety of Photobiomodulation in Dry Age-Related Macular Degeneration (LIGHTSITE III: 24-Month Analysis).

Journal Article Retina · March 3, 2026 PURPOSE: To evaluate the safety and efficacy of multiwavelength photobiomodulation (PBM) in nonexudative (dry) age-related macular degeneration (AMD). METHODS: LIGHTSITE III employed a double-masked, randomized, sham-controlled, parallel-group, prospective ... Full text Link to item Cite
View All Publications

Recent Grants


View All Grants

Education

University of California San Francisco, School of Medicine · 1983 M.D.